Lymphocyte subsets in haematological patients with COVID-19: Multicentre prospective study.
CD4/CD8 ratio
COVID-19
Haematological malignancies
Lymphocyte subsets
NK cells
T cells
TCR ɣ/ƍ cells
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
08
09
2020
revised:
20
10
2020
accepted:
03
11
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
19
11
2020
Statut:
ppublish
Résumé
The role of immune dysregulation in the course and prognosis of COVID-19 is not clearly established. In particular, immune status in specific populations such as haematological patients, who have an impaired immunological system, has not been described so far. Here, we performed a comprehensive analysis of peripheral blood lymphocyte subsets in 27 SARS-CoV-2-infected patients, including 16 patients with haematological malignancies. We identified T cell subpopulations, B cells, NK cells and TCR α/ß and ɣ/ƍ-expressing T cells during COVID-19 infection, with significant changes observed in immune profiles during the course of disease, especially in haematological patients. We observed an increase in activated T lymphocytes (CD3+HLA-DR+ and CD3+CD8+HLA-DR+) in the early stages of SARS-CoV-2 infection with a concomitant decrease in the CD4/CD8 ratio in haematological patients compared to non-haematological patients affected by COVID-19. We also found a decrease in ɣ/ƍ T cells in both studied groups of patients, with lower numbers of CD25+ T cells and CD16+CD56+ NK cells in haematological patients compared to non-haematological patients with COVID-19. Our findings demonstrate, for the first time, impaired adaptive immunity in patients with haematological malignancies infected with COVID-19, resulting in impaired cellular immune responses to SARS-CoV-2. This warrants further investigation of this disease group in COVID-19 patient cohorts.
Identifiants
pubmed: 33204385
doi: 10.1016/j.tranon.2020.100943
pii: S1936-5233(20)30435-6
pmc: PMC7657028
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100943Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests
Références
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Lancet. 2020 Apr 11;395(10231):1225-1228
pubmed: 32178769
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
J Infect Dis. 2020 Jun 29;222(2):198-202
pubmed: 32379887
Clin Chim Acta. 2020 Sep;508:110-114
pubmed: 32405080
J Infect. 2020 Jul;81(1):e51-e60
pubmed: 32315725
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Front Immunol. 2015 Jan 30;5:687
pubmed: 25688241
Klin Wochenschr. 1990 Apr 17;68(8):393-6
pubmed: 1971856
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
J Clin Virol. 2020 Jun;127:104361
pubmed: 32344320
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Leukemia. 2006 Jan;20(1):29-34
pubmed: 16281063
J Cell Mol Med. 2020 Oct;24(19):11603-11606
pubmed: 32864865
J Infect Dis. 2020 May 11;221(11):1762-1769
pubmed: 32227123
Int J Infect Dis. 2020 Jul;96:131-135
pubmed: 32376308
Clin Exp Immunol. 1993 Sep;93(3):337-43
pubmed: 8103715
Cytometry A. 2020 Aug;97(8):772-776
pubmed: 32542842